Duck Hepatitis A Virus

Overview and Taxonomy of Duck Hepatitis A Virus

Duck Hepatitis A Virus (DHAV) represents a significant etiological agent within the global waterfowl industry, responsible for the acute, highly contagious, and often fatal disease known as duck viral hepatitis (DVH). The economic and animal health impact of DHAV is profound, with outbreaks capable of causing mortality rates exceeding 90% in susceptible duckling populations, a fact that positions it as a pathogen of critical concern to the World Organisation for Animal Health (WOAH) and national veterinary authorities worldwide [2, 5, 6]. Understanding the foundational taxonomy, genomic architecture, and evolutionary dynamics of DHAV is not merely an academic exercise; it is a prerequisite for the rational design of diagnostic tools, effective vaccines, and sustainable control strategies. This section provides a comprehensive, deep analysis of the virus’s classification, structural biology, genetic diversity, and the molecular mechanisms that underpin its pathogenicity and evolution.

Taxonomic Classification and Genomic Architecture

DHAV is classified within the family Picornaviridae, a large and diverse family of small, non-enveloped, positive-sense single-stranded RNA viruses. However, DHAV is distinct from other picornaviruses, being the sole member of the genus Avihepatovirus [1, 2, 25]. This genus-level distinction is based on significant differences in genome organization, phylogenetic divergence, and biological properties compared to other picornavirus genera such as Enterovirus, Hepatovirus, or Kobuvirus. The viral genome is approximately 7.7 kb in length and exhibits the canonical picornavirus organization: a single, large open reading frame (ORF) flanked by a highly structured 5′ untranslated region (UTR) and a 3′ UTR terminating in a poly(A) tail [1, 22, 31].

The 5′ UTR is of paramount importance as it contains an internal ribosome entry site (IRES) element, which directs cap-independent translation of the viral polyprotein [22, 27]. This IRES-driven translation is a hallmark of picornaviruses and allows the virus to hijack the host cell’s translational machinery even when cap-dependent host translation is shut off. The 3′ UTR and poly(A) tail are not merely passive structures; they are critical for maintaining viral genome stability, enhancing IRES-mediated translation efficiency, and are essential for the initiation of negative-strand RNA synthesis during genome replication [22]. The polyprotein is co- and post-translationally processed by viral proteases (primarily 3C protease) into four structural proteins (VP0, VP3, VP1) that form the icosahedral capsid, and seven non-structural proteins (2A, 2B, 2C, 3A, 3B, 3C, 3D) involved in genome replication, host cell manipulation, and proteolytic processing [1, 12, 21].

Serotypes and Genotypes: The DHAV-1, DHAV-2, and DHAV-3 Paradigm

Historically, DHAV was classified into three distinct serotypes based on cross-neutralization assays. DHAV-1 is the classic, globally distributed serotype first identified in the United States in 1945 and remains the most widespread cause of DVH outbreaks in duck-producing regions worldwide [6, 26]. DHAV-2 and DHAV-3 were initially identified in Taiwan and subsequently in other parts of Asia, with DHAV-3 now recognized as a major and increasingly dominant pathogen, particularly in China, South Korea, and Vietnam [2, 14, 15, 17]. Crucially, there is no cross-protection between these serotypes; immunity to DHAV-1 does not protect against DHAV-3 infection, a factor that has complicated vaccination strategies and driven the need for multivalent vaccines [4, 6, 30].

Genetically, these serotypes correspond to distinct genotypes. Phylogenetic analyses, particularly of the VP1 gene, the major capsid protein that contains critical neutralizing epitopes, have further subdivided DHAV-1 and DHAV-3 into multiple sub-genotypes or clades. Full-length genome-based studies have sorted global DHAV-1 strains into at least seven sub-groups and DHAV-3 strains into five sub-groups, revealing a complex and dynamic genetic landscape [9]. For instance, Egyptian DHAV-1 strains have been classified into distinct genetic groups (e.g., Group 1 and Group 4), with recent isolates clustering separately from older vaccine strains, indicating ongoing genetic drift and the emergence of new lineages [13, 18, 23]. Similarly, DHAV-3 strains from Egypt, first reported in 2020, have been shown to cluster with Chinese and Korean-Vietnamese strains, suggesting a relatively recent introduction and transcontinental spread [3, 15, 17]. This genetic diversity within serotypes has direct implications for vaccine efficacy, as field variant strains may exhibit reduced susceptibility to antibodies elicited by older, prototype vaccine strains [4].

Molecular Biology of Virulence and Pathogenesis

The molecular determinants of DHAV virulence are multifactorial, involving proteins from both the structural and non-structural regions. The VP1 protein is a major focus of research, as it is the primary target for neutralizing antibodies and contains hypervariable regions (HVRs) that are hotspots for amino acid substitutions [1, 15, 18]. Specific mutations in the C-terminus of VP1, such as I180T, G184E, D193N, and M213I, have been associated with altered pathogenicity and antigenic variation in Egyptian DHAV-1 isolates [18]. Furthermore, a unique escape mutation, S178Y, in a conserved antigenic determinant of VP1 was identified in a recent Egyptian DHAV-1 isolate, demonstrating the virus’s capacity for immune evasion even in the face of vaccination [1].

The non-structural proteins are equally critical. The 2B protein of DHAV-1 functions as a viroporin, a small hydrophobic transmembrane protein that oligomerizes to form pores in host cell membranes. This activity disrupts calcium ion homeostasis, leading to an increase in intracellular Ca²⁺ concentration, which in turn triggers incomplete autophagy, a process where autophagosomes form but fail to fuse with lysosomes, potentially providing a protected niche for viral replication [12]. The 3C protease is a multifunctional enzyme responsible for cleaving the viral polyprotein. Beyond this, it also cleaves host proteins to subvert cellular processes. A key target is the poly(A)-binding protein (PABP) , a critical factor for host mRNA translation and stability. DHAV 3C protease cleaves PABP at a specific site (Q367/G368), leading to the inhibition of host cell protein synthesis while simultaneously facilitating viral replication [21]. The 3D polymerase (3Dpol) , the viral RNA-dependent RNA polymerase, is essential for genome replication and has been shown to possess a functional nuclear localization signal (NLS). The translocation of 3Dpol/3CD into the nucleus is thought to contribute to the shutoff of host cell transcription, a common strategy among picornaviruses to redirect cellular resources towards viral propagation [29].

Host-Virus Interactions and Immune Evasion

DHAV has evolved sophisticated mechanisms to evade and manipulate the host immune response. The virus can induce a cytokine storm, a hyperinflammatory state characterized by the massive release of pro-inflammatory cytokines (e.g., IL-6, IL-1β, IFN-α, IFN-γ), which is a primary driver of the rapid, severe liver damage and high mortality seen in acute infections [7, 19, 24]. The virulent DHAV-1 CH strain, for example, triggers a severe cytokine storm in the liver, leading to ecchymotic hemorrhages and rapid death, whereas an attenuated strain does not [19].

A particularly intriguing immune evasion strategy involves exosome-mediated transmission. DHAV-1 has been shown to hijack the host’s exosomal pathway, packaging complete viral genomic RNA, partial viral proteins, and even virions into exosomes. These exosomes can then deliver infectious virus to new cells in a manner that is completely resistant to neutralization by high titers of specific antibodies [10]. This mechanism provides a “Trojan horse” route for viral spread, allowing DHAV to bypass humoral immunity and establish a productive infection even in the presence of a robust antibody response. Additionally, the host protein placenta-specific 8 (PLAC8) has been identified as a proviral factor for DHAV-1. PLAC8 expression is induced upon infection and acts by suppressing the TLR7-MyD88-dependent signaling pathway, thereby reducing the production of type I interferons and other antiviral cytokines, which ultimately facilitates viral replication [8]. These intricate host-virus interactions highlight the complex battlefield within the infected duckling and underscore the challenges in developing broadly effective therapeutics.

Genetic Evolution, Recombination, and Global Epidemiology

The evolution of DHAV is driven by two primary forces: the accumulation of point mutations due to the error-prone nature of the RNA-dependent RNA polymerase, and recombination between different strains or even serotypes. Recombination is a powerful evolutionary mechanism that can generate novel viruses with altered virulence, host range, or antigenicity. Intergenotype recombination events between DHAV-1 and DHAV-3 have been documented, with a hotspot identified in the VP0 region [11]. Furthermore, intragenotype recombination within DHAV-1 is also common, and a recombinant DHAV-1 strain (Egypt-10/2019) was identified in Egypt, highlighting the ongoing evolution of the virus in the field [13]. The 5′ end of the genome and the upstream region of the capsid coding sequence have been identified as recombination hotspots [9].

Epidemiologically, the global landscape of DHAV has shifted dramatically in the last two decades. While DHAV-1 was historically dominant, DHAV-3 has emerged as the predominant genotype in China and other parts of Asia since approximately 2013 [5, 14]. This shift is attributed to the widespread use of DHAV-1 vaccines, which effectively controlled DHAV-1 but left a niche for the antigenically distinct DHAV-3 to expand [5, 14]. Meta-analyses of prevalence data from mainland China between 2009 and 2021 estimated that DHAV-3 accounted for 49% of typed samples, compared to 38% for DHAV-1 [5]. The virus has also spread beyond Asia, with DHAV-3 being first reported in Egypt in 2020, and subsequent studies confirming its dual circulation with DHAV-1 in North African duck populations [3, 15, 17]. This geographic expansion, coupled with the virus’s ability to undergo recombination and antigenic drift, necessitates continuous global surveillance. The emergence of variant strains that can cause atypical pathology, such as the pancreatitis-type DHAV-1 which primarily targets the pancreas rather than the liver, further complicates diagnosis and control [20, 28]. The evidence of possible vertical transmission of DHAV-1 from breeding ducks to their progeny via the egg adds another layer of complexity to disease management, as it provides a mechanism for the virus to persist within a flock across generations [16].

Molecular Pathogenesis and Host-Virus Interactions

Duck Hepatitis A Virus (DHAV), a member of the genus Avihepatovirus within the family Picornaviridae, exerts its devastating effects through a sophisticated, multi-layered molecular pathogenesis that involves direct viral cytopathology, subversion of host cellular machinery, and a profoundly dysregulated immune response. The acute, highly fatal nature of duck viral hepatitis (DVH), particularly in ducklings under three weeks of age, is the culmination of a complex interplay between viral replication kinetics, host susceptibility factors, and the induction of immunopathologic injury. Understanding these interactions at the molecular level is paramount for the development of rational therapeutic interventions and next-generation vaccines, as the virus continues to evolve through mutation and recombination, challenging existing control measures.

Host Cell Entry, Receptor Engagement, and Viral Dissemination

The initial stages of DHAV infection are characterized by efficient attachment and entry into hepatocytes, the primary target cell. While a definitive cellular receptor for DHAV remains uncharacterized, the structural proteins, particularly VP1 and VP3, are critically involved in this process. The VP1 protein is the major capsid protein and harbors critical neutralizing epitopes [1, 45] and a hypervariable region (HVR) that is under significant immune pressure [15]. Antigenic analysis of field strains has revealed escape mutations in VP1, such as the S178Y substitution, which can alter antigenic determinants and potentially facilitate immune evasion [1]. Crucially, VP3 has also been demonstrated to mediate host cell adsorption. Antibodies directed against the VP3 protein significantly reduce viral copy numbers in attachment assays, though not as effectively as anti-DHAV-1 antibodies, suggesting that while VP3 is a key player in adsorption, it is not the sole factor, likely acting in concert with VP1 and other surface determinants [44].

Following replication, DHAV has evolved a unique mechanism for intercellular dissemination that bypasses standard antibody neutralization. Seminal research has demonstrated that DHAV-1 utilizes exosomes, nanosized extracellular vesicles, for non-lytic transmission. Complete DHAV-1 genomic RNA, partial viral proteins, and even entire virions are packaged into exosomes derived from infected duck embryo fibroblasts (DEFs). This exosome-mediated route establishes a productive infection in vivo and in vitro that is remarkably resistant to high titers of neutralizing antibodies [10]. This represents a potent immune evasion strategy, allowing the virus to spread silently within the host, effectively shielded from the humoral immune response. Furthermore, evidence of possible vertical transmission from breeding ducks to ducklings through the embryo has been documented, with DHAV-1 RNA isolated from non-embryonated eggs, embryos, and newly hatched ducklings, further complicating disease control in breeding flocks [16].

Subversion of Host Cellular Machinery: Translation, Cell Cycle, and Autophagy

Once inside the host cell, DHAV commandeers the cellular machinery for its own benefit, initiating a cascade of events that culminate in cellular dysfunction and death. A hallmark of DHAV pathogenesis is the global shutoff of host cellular protein synthesis, a strategy common to many picornaviruses to favor viral mRNA translation. DHAV-1 induces this translation shutoff in a eIF2α phosphorylation-dependent manner [39]. The virus activates two key stress-activated kinases, PERK and GCN2, leading to the phosphorylation of eIF2α, which inhibits the formation of the 43S pre-initiation complex and halts cap-dependent host translation. Remarkably, the role of GCN2 in this process is a unique finding for picornaviruses and distinguishes DHAV from other family members [39]. This translational arrest is essential, as inhibiting eIF2α phosphorylation restores cellular translation. To further manipulate the translational environment, the viral 3C protease directly cleaves the host poly(A)-binding protein (PABP) [21]. This cleavage, located between Q367 and G368, generates N- and C-terminal fragments. While full-length PABP and its C-terminal domain inhibit viral replication, the cleavage event itself is a sophisticated viral strategy to modulate the host translation machinery, likely to fine-tune the balance between cap-dependent and IRES-driven translation [21]. The Insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1) further enhances this process by specifically interacting with the DHAV-1 3' UTR, strongly increasing IRES-mediated translation efficiency without affecting viral RNA replication itself [27]. The 3' UTR and poly(A) tail are both critical for maintaining genome stability and enhancing IRES-mediated translation, with at least 20 adenines required for optimal replication [22].

Concurrent with translation shutoff, DHAV-1 manipulates the host cell cycle and induces the formation of replication platforms. DHAV-1 infection causes a significant arrest of DEFs in the S phase of the cell cycle, increasing the proportion of S-phase cells by over 54% at 48 hours post-infection. This S-phase arrest is specifically mediated by the viral non-structural protein 3D (the RNA-dependent RNA polymerase), which promotes a cellular environment favorable for viral replication [40]. Remarkably, DHAV-3 has been shown to induce cell cycle changes that are associated with the expression level of the host restriction factor IFITM1. In susceptible duck lines, DHAV-3 infection leads to the upregulation of cyclins (CCND1, CCNE1) and CDK6, linking viral pathogenesis to the dysregulation of cell cycle progression [36].

Another critical host process subverted by DHAV is autophagy. The 2B protein of DHAV-1 functions as a viroporin, a small hydrophobic transmembrane protein that oligomerizes and forms pores in cellular membranes, disturbing ion homeostasis. Expression of the 2B protein leads to a significant elevation of intracellular Ca²⁺ concentration and upregulates the conversion of LC3-I to LC3-II, a hallmark of autophagosome formation [12]. However, this autophagy is incomplete or non-canonical. The autophagic substrate p62/SQSTM1 is not efficiently degraded, and autophagosomes fail to colocalize with lysosomes, indicating a block in autophagic flux [12]. This incomplete autophagy may create membranous scaffolds that are essential for viral genome replication, a mechanism exploited by many positive-sense RNA viruses. The importance of autophagosome formation for DHAV replication is underscored by the finding that phosphorylated polysaccharides (e.g., from Codonopsis pilosula) exert their antiviral effect by inhibiting autophagosome formation, thereby directly suppressing viral genome replication [38].

Modulation of Innate Immunity and the Cytokine Storm

The host's innate immune system is the first line of defense, and DHAV has evolved a sophisticated arsenal to subvert it. A central mechanism involves the host protein Placenta-Specific 8 (PLAC8) . Upon DHAV-1 infection, PLAC8 expression is significantly induced in immune organs. This protein then acts to suppress the Toll-like receptor 7 (TLR7)-MyD88-NF-κB signaling pathway, leading to decreased expression of type I interferon (IFN) and IL-6 [8]. By inhibiting this crucial antiviral pathway, PLAC8 actively promotes DHAV-1 replication; conversely, RNA interference against PLAC8 markedly inhibits viral propagation [8]. This highlights how the host's own regulatory mechanisms can be hijacked by the virus to dampen the innate antiviral response.

Despite these viral countermeasures, DHAV infection, particularly with virulent strains, triggers an overwhelming and dysregulated innate immune response known as a cytokine storm, which is primarily responsible for the rapid and fulminant death of young ducklings. Experimental infection with a virulent DHAV-1 strain results in massive infiltration of red blood cells into the liver and the upregulation of a vast array of pro-inflammatory cytokines, including IFN-α, IL-6, IL-8, IL-10, and IL-1β [19, 24]. This severe inflammatory response causes ecchymotic hemorrhages on the liver surface and is a key factor in the rapid onset of mortality [19]. The Type I interferon response, while intended to be protective, becomes a double-edged sword. Proteomic analysis of DHAV-3-infected livers reveals that interferon-induced protein synthesis, driven by the RIG-I-like, Toll-like, and NOD-like receptor signaling pathways, paradoxically supports viral genome replication and aggravates liver damage [42].

The genetic basis for susceptibility to this cytokine storm is becoming increasingly clear. Through selective breeding, resistant (Z8) and susceptible (Z7) Pekin duck lines have been established. Susceptible ducklings exhibit a dramatically stronger inflammatory response, with significantly higher expression levels of pattern recognition receptors (e.g., TLR4/7, RIG-I, MDA5) and cytokines (e.g., IL-2, IL-6, IFN-γ) in the liver compared to their resistant counterparts [24]. This indicates that a hyperactive, rather than a deficient, innate immune response is a hallmark of susceptibility. The NOD1 protein has been specifically linked to this susceptibility, showing higher expression in the livers of susceptible ducks after DHAV-3 infection, and its expression level directly influences viral copy number [37]. Conversely, resistance is associated with the CRHR2 gene, which has undergone 134 mutations during selective breeding [34]. The virus also exploits epitranscriptomic modifications, such as N6-methyladenosine (m6A) , to modulate host gene expression. Attenuated DHAV infection is associated with much higher levels of m6A mRNA modification in the liver compared to virulent infection, suggesting a virulence-dependent regulation of this modification that influences mRNA stability and expression of genes involved in oxidation-reduction and antiviral immune responses [35].

Tissue Tropism, Apoptosis, and Metabolic Dysregulation

DHAV is a pantropic virus, but its primary target is the liver, where it establishes the highest viral RNA loads [31]. Beyond the liver, the virus efficiently infects and replicates in lymphoid organs, exhibiting a distinct lymphoid tissue tropism. DHAV-1 can persist in the spleen, thymus, and bursa of Fabricius for over six months, contributing to viremia and chronic infection. This persistence is linked to the dysregulation of T-cell homing and priming, as the virus alters the expression of CCL19, CCL21, MHC-I, and MHC-II, skewing the immune response towards a Th2 profile due to consistently higher levels of IL-4 compared to IL-2 and IFN-γ [48]. Within the liver, specific DHAV-1 subtypes can also target the pancreas, inducing a distinct pancreatitis phenotype characterized by viral replication in acinar epithelial cells, pancreatic hemorrhage, and apoptosis of acinar cells, contrasting with the classic hepatitis presentation [20, 28].

At the cellular level, DHAV triggers programmed cell death through apoptosis. The VP1 protein contains a B-cell epitope (¹⁷⁴PAPTST¹⁷⁹) that is a target for antibody binding [45]. However, the primary driver of apoptosis is the VP3 protein. Expression of VP3 in DEFs induces significant apoptosis, characterized by nuclear fragmentation, caspase-3 activation, and a decrease in mitochondrial membrane potential. Mechanistically, VP3 upregulates the transcription of pro-apoptotic factors like Bak, Cyt c, and Apaf-1, indicating that it activates the intrinsic, mitochondrion-mediated apoptotic pathway [44]. This caspase-3-mediated apoptosis is a direct contributor to the severe hepatic necrosis observed in infected ducklings.

Finally, DHAV infection induces profound metabolic dysregulation, which correlates with the severity of disease. Hypoglycemia is a notable sign of fatal DHAV-3 infection, resulting from a disruption of glucose metabolism. Transcriptomic analyses reveal that DHAV-3 infection in susceptible ducks leads to cytokine-mediated activation of the PI3K-AKT and JAK-STAT pathways, which in turn downregulates key gluconeogenic enzymes like G6PC and ACAT1, leading to a suppression of glucose synthesis [43]. Liver damage is also reflected in the dramatic elevation of serum enzymes such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) , which are direct markers of hepatocellular injury and are significantly higher in susceptible duck breeds [24, 33]. In contrast, Pekin ducks show lower lipase levels compared to Muscovy ducks, indicating breed-specific differences in the metabolic response to infection [33].

Genetic Determinants of Virulence and Attenuation

The molecular basis of DHAV virulence lies in a constellation of mutations across the genome. The attenuation of highly virulent field strains through serial passaging in embryonated chicken or duck eggs has pinpointed several key mutations that are responsible for the loss of pathogenicity. In DHAV-1, the commercial vaccine strain CH60 (passaged 60 times) shows significantly lower viral titers in the liver (10⁴·⁹ copies/mg vs. 10⁸·⁴ copies/mg for the virulent CH strain) and fails to induce the catastrophic cytokine storm, directly linking replication efficiency to immunopathology [19]. The attenuated HB80 strain of DHAV-3 harbors seven amino acid substitutions compared to its virulent parent, with two critical changes occurring in the hypervariable region of VP1 and the polymerase-encoding 3D region, suggesting these are key attenuating determinants [32]. Similarly, the SD70 DHAV-3 vaccine strain contains 12 amino acid substitutions acquired during passage [41].

For another DHAV-3 strain, the attenuation phenotype was mapped to just two amino acid substitutions: Y164N in the VP0 capsid protein and L71I in the 2C protein. These mutations resulted in significantly reduced viral RNA loads in the liver and a concurrent downregulation of innate immune genes, demonstrating that subtle genetic changes can have a profound effect on both replication capacity and host immune activation [46]. The functional consequences of these changes are linked to codon usage bias. Comparative analysis shows that attenuated strains exhibit a lower protein expression efficiency than virulent strains due to fixed single nucleotide polymorphisms (SNPs) selected during passage, which correlates with a more robust Tc cell response in the spleen and thymus [49]. Furthermore, the ability of fetal calf serum to inhibit DHAV replication at the adsorption stage provides an important in vitro clue about the host barriers the virus must overcome to establish infection [47, 50]. The ongoing evolution of DHAV is also shaped by recombination, a major driver of genetic diversity with hotspots identified at the 5' end of the genome and the upstream region of the capsid [9, 11]. Intergenotype recombination between DHAV-1 and DHAV-3 in the VP0 region has been documented, leading to the emergence of novel recombinant viruses that can alter viral fitness and potentially vaccine efficacy [11, 13].

Global Epidemiology and Disease Impact of Duck Hepatitis A Virus

Duck Hepatitis A Virus (DHAV) represents one of the most significant viral pathogens confronting the global waterfowl industry, imposing a substantial economic burden through acute, highly fatal hepatitis in young ducklings. As the primary etiological agent of Duck Viral Hepatitis (DVH), DHAV is classified within the genus Avihepatovirus of the family Picornaviridae and is recognized by the World Organisation for Animal Health (WOAH) as a notifiable disease due to its capacity for rapid dissemination and severe production losses. The global epidemiological landscape of DHAV has undergone profound shifts over the past two decades, characterized by the emergence and dominance of new serotypes, complex patterns of co-infection with other immunosuppressive duck pathogens, and the transcontinental spread of viral lineages that challenge existing control measures.

Global Distribution and Serotype Dynamics

The global epidemiology of DHAV is fundamentally defined by the distribution and interplay of its three recognized serotypes: DHAV-1, DHAV-2, and DHAV-3. DHAV-1, the first serotype identified and historically the most widespread, has been documented across Asia, Europe, Africa, and North America since its initial characterization in 1945 [6, 11]. Outbreaks in Japan were first recorded in 1963, with a significant re-emergence reported in Hyogo Prefecture in 2015, where a virulent strain exhibiting 96% nucleotide identity to the Chinese HB02 isolate caused a mortality rate of approximately 76% in affected ducklings [26]. In Hungary, a major epizootic involving DHAV-1 swept through duck populations between 2004 and 2005, providing key genomic data for understanding European viral evolution [11]. However, the most consequential epidemiological event in recent years has been the dramatic rise of DHAV-3. While DHAV-2 and DHAV-3 were initially considered largely restricted to Southeast Asia, DHAV-3 has now emerged as the predominant serotype across mainland China, South Korea, Vietnam, and, critically, has made a significant incursion into Egypt [2, 5, 6, 14].

This serotype shift is most starkly illustrated in China, the world's largest duck producer. A comprehensive meta-analysis of data spanning 2009 to 2021, encompassing 689,549 cases across 14 provinces, revealed that DHAV-3 accounted for 49% (95% CI: 31-68%) of typed samples, surpassing DHAV-1 which constituted 38% (95% CI: 21-56%) [5]. This represents a fundamental reversal from the epidemiological situation prior to 2013, where DHAV-1 was overwhelmingly dominant [5, 14]. The widespread and highly effective deployment of live attenuated DHAV-1 vaccines in China since 2013 is widely credited with suppressing DHAV-1 circulation, thereby creating an ecological niche into which the antigenically distinct DHAV-3 has expanded [5, 6]. Critically, cross-protection between DHAV-1 and DHAV-3 is negligible; vaccination against one serotype does not confer meaningful immunity against the other, a fact that has driven the need for multivalent vaccine strategies [4, 30, 32]. This dynamic is not unique to China. In South Korea, phylogenetic analyses have identified distinct clusters of DHAV-3 field strains that are genetically divergent from vaccine strains, with cross-protection studies demonstrating that while DHAV-3 vaccines can provide robust protection against both homologous and heterologous challenge, DHAV-1 vaccines offer only 40-60% survival against emerging heterologous DHAV-1 variants [4].

The Emergence of DHAV-3 in Africa

The most significant recent expansion of the DHAV-3 epidemiological range is its establishment in Egypt, marking the first confirmed presence of this serotype outside of Asia [15, 17]. Prior to 2019, Egyptian duck flocks were believed to be affected only by DHAV-1, but extensive surveillance following severe outbreaks in vaccinated flocks in the Sharkia and northern governorates between 2016 and 2019 revealed a dual circulation of both serotypes [15, 17, 23]. A seminal study in 2019 detected DHAV-3 RNA in 33.3% of positive samples from 54 flocks, with phylogenetic analysis confirming these Egyptian strains formed a distinct cluster, geographically separated from Asian references, yet sharing a common ancestor with Chinese and Korean-Vietnamese lineages [17]. Subsequent metagenomic next-generation sequencing (m-NGS) has further confirmed the presence of DHAV-3 in Egypt, with one study identifying a strain that shared 96.8-100% nucleotide similarity with other Egyptian isolates, but intriguingly exhibiting distinct separation from reference strains [33]. The introduction of DHAV-3 into Egypt poses a severe challenge, as the locally used DHAV-1 vaccines are genetically and antigenically distant, sharing only 67.6% nucleotide identity in the VP1 gene with DHAV-3 field isolates, leaving a large, naive duck population vulnerable [15, 33].

Furthermore, the Egyptian epidemiological picture is complicated by the co-circulation of highly divergent DHAV-1 strains. A 2025 study utilizing complete genome sequencing via NGS identified a DHAV-1 isolate from an outbreak in Benha that showed 99.9% identity to a 2004 Hungarian strain, suggesting a possible long-distance introduction event over a decade prior [1]. This same study identified a critical antigenic escape mutation, S178Y, within a conserved determinant of the VP1 protein, which, while not rendering the current vaccine ineffective, highlights the ongoing selective pressure and potential for immune evasion [1]. The situation is further compounded by the first identification of concurrent infections of DHAV-3 with a novel duck astrovirus (DAstV-5) in Egypt, underscoring the complexity of the viral ecosystem affecting ducklings and the need for advanced metagenomic surveillance tools [3].

Mixed Infections and Co-Circulation Patterns

The contemporary epidemiology of DHAV is no longer defined by single-pathogen infections. The intensification of duck production and the immunosuppressive nature of DHAV itself have facilitated a rising trend of mixed infections with other viral and bacterial agents, which significantly complicates clinical diagnosis, exacerbates disease severity, and increases economic losses [2]. Beyond the DHAV-1/DHAV-3 co-circulation, diagnostic surveys have revealed frequent co-infections with novel duck reovirus (NDRV), duck Tembusu virus (DTMUV), and duck astroviruses (DAstV-3) [51-53]. A recent multiplex RT-qPCR survey of 215 clinical duck samples in China detected DHAV-3 at a rate of 6.27% and DHAV-1 at 5.58%, but also identified co-infection rates of DHAV-3 with DTMUV at 5.58% and triple infections involving DHAV-3, DTMUV, and NDRV at 0.05% [52]. Similarly, a duplex qPCR study targeting DHAV-1 and DAstV-3 in 34 clinical samples found a positivity rate of 14.71% for DHAV-1 and 8.82% for DAstV-3, with a 2.94% co-infection rate [53]. These mixed infections often present with overlapping clinical signs (neurological symptoms, hepatitis), making differential diagnosis without molecular tools impossible and leading to potential underestimation of the true disease burden [51, 56].

Host Susceptibility, Transmission, and Economic Toll

The disease impact of DHAV is inextricably linked to host age, breed, and the specific viral strain. Ducklings under three weeks of age are most susceptible, with mortality rates in naive flocks often reaching 90-100% [6]. The underlying mechanisms for this age restriction are multifaceted, involving the immaturity of the duckling's innate immune system. Critically, a severe, uncontrolled cytokine storm, characterized by the massive upregulation of pro-inflammatory cytokines like IL-6, IFN-α, and IL-1β in the liver, has been identified as the primary driver of rapid death in DHAV-1 and DHAV-3 infections, rather than direct viral cytolysis alone [7, 19, 24]. The hypervirulent DHAV-1 CH strain, for instance, induces a viral load of 10⁸.⁴ copies/mg in the liver, triggering a cytokine cascade that leads to ecchymotic hemorrhages and fulminant hepatic necrosis, while an attenuated strain with a 10⁴.⁹ copies/mg load fails to induce such a lethal response [19].

Breed susceptibility introduces another layer of epidemiological complexity. Controlled experimental infections have demonstrated that Pekin ducklings are significantly more susceptible to severe disease from DHAV-3 than Muscovy ducklings. Infected Pekin ducklings exhibit higher cloacal viral shedding, more pronounced elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and more severe histopathological lesions in the liver, heart, and brain compared to Muscovy ducklings [18, 33]. Furthermore, the existence of genetically distinct pathotypes, such as the "pancreatitis-type" DHAV-1a, which causes pancreatic hemorrhage and necrosis with minimal liver involvement, demonstrates that the clinical impact and target organ tropism can vary dramatically even within the same serotype [20, 28].

The economic impact of DHAV extends beyond acute mortality in ducklings. Evidence of vertical transmission has been established, with DHAV-1 RNA detected in 32.2% of eggs and embryos from breeder flocks experiencing egg drop syndrome, indicating that the virus can compromise hatchery output and serve as an insidious source of infection for subsequent generations [16]. Adult ducks, while often asymptomatically infected or showing only a transient drop in egg production, can serve as long-term viral reservoirs. DHAV-1 has been shown to persist in the lymphoid tissues of mature ducks for over six months, contributing to chronic viremia and continuous environmental shedding [48, 54, 55]. Globally, the collective economic losses from DHAV are staggering, with the meta-analytic incidence in China alone estimated at 12% (95% CI: 3-20%) and a mortality rate of 11% (95% CI: 2-19%), figures that likely underrepresent the true subclinical and chronic losses [5]. The development of rapid point-of-care diagnostic tools, such as the RPA-CRISPR Cas12a/Cas13a platform (DRCFS), which can detect DHAV-3 and NDRV with a sensitivity of 100 copies/μL in 35 minutes without complex instrumentation, represents a critical advancement for on-site surveillance and the timely implementation of control measures in this dynamic epidemiological landscape [51].

Molecular and Antigenic Characterization of DHAV Strains

The molecular landscape of Duck Hepatitis A Virus (DHAV) is defined by a complex interplay of genomic organization, phylogenetic divergence, and antigenic plasticity. As a member of the genus Avihepatovirus within the family Picornaviridae, DHAV possesses a single-stranded, positive-sense RNA genome that typically ranges from approximately 7.7 to 7.8 kb in length. The genomic architecture is highly characteristic, comprising a 5′ untranslated region (UTR) harboring an internal ribosome entry site (IRES), a single large open reading frame (ORF) encoding a polyprotein precursor, and a 3′ UTR followed by a poly(A) tail [1, 22]. The polyprotein is co- and post-translationally cleaved by viral proteases into structural proteins (VP0, VP3, and VP1) that form the icosahedral capsid, and non-structural proteins (2A, 2B, 2C, 3A, 3B, 3C, and 3D) essential for replication and host interaction [1, 11]. The complete genome sequencing of isolates from diverse geographic regions, including Egypt, China, and Hungary, has been instrumental in delineating the evolutionary relationships and molecular determinants of virulence among DHAV strains [1, 11, 13].

Genomic Phylogeny and Evolution

Phylogenetic analyses based on complete genome sequences have definitively classified DHAV into three distinct serotypes or genotypes: DHAV-1, DHAV-2, and DHAV-3. Among these, DHAV-1 is globally distributed, whereas DHAV-2 and DHAV-3 are predominantly reported in Asia, with DHAV-3 emerging as a significant pathogen in China and other East Asian countries since the early 2000s [1, 2, 11]. Whole-genome-based phylogenies have further resolved DHAV-1 isolates worldwide into at least seven sub-groups, while DHAV-3 strains cluster into five distinct sub-groups, reflecting substantial genotypic diversity [9]. Molecular epidemiological studies in China from 2010 to 2015 documented a pronounced epidemiological shift: DHAV-1 was the predominant genotype circulating between 2010 and 2012, correlating with the widespread use of a licensed live attenuated DHAV-1 vaccine beginning in 2013. This was followed by a marked increase in the isolation rate of DHAV-3 between 2013 and 2015, suggesting that vaccine-induced immunity against DHAV-1 did not provide cross-protection against the emerging DHAV-3 strains, thereby facilitating their expansion [14]. This pattern has been corroborated by meta-analyses indicating that DHAV-3 now accounts for a higher proportion of clinical cases than DHAV-1 in mainland China [5, 14].

The evolutionary dynamics of DHAV are driven by both point mutations and recombination. The estimated substitution rates for DHAV-1 protein-coding regions range from approximately 5.6 × 10⁻⁴ to 1.1 × 10⁻³ substitutions per site per year, which are slightly lower than those reported for many other picornaviruses but still indicative of active genomic drift [11]. Critically, recombination has been identified as a major force shaping DHAV evolution. Intra-genotype recombination events are common within DHAV-1, and, more significantly, inter-genotype recombination between DHAV-1 and DHAV-3 has been documented, with a recombination hot spot located in the VP0 region [11]. Additionally, the 5′ end of the genome and the upstream region of the capsid coding sequence have been identified as recombination hot spots, contributing to the generation of novel chimeric viruses with potentially altered pathogenic and antigenic properties [9]. The emergence of a new recombinant DHAV-1 strain in Egypt (Egypt-10/2019) exemplifies the constant evolutionary pressure and the potential for recombination to generate genetic diversity that may escape current vaccine-induced immunity [13].

Antigenic Determinants and the VP1 Gene

The VP1 capsid protein is the primary antigenic determinant and the main target for neutralizing antibodies against DHAV, making its genetic and structural characterization paramount for understanding antigenic diversity and vaccine efficacy [1, 4, 57]. The VP1 gene exhibits considerable sequence variability, particularly within its C-terminal region, which contains several hypervariable regions (HVRs). DHAV-1 strains typically possess three HVRs, whereas DHAV-3 strains have at least one major HVR in VP1 [15]. Amino acid substitutions within these HVRs are often associated with altered antigenicity and can lead to immune evasion. For instance, a unique escape mutation, S178Y (serine to tyrosine at position 178), was identified in the VP1 of a DHAV-1 field isolate from Egypt (Du/Egy/Benha/2020/DHAV-1) within a conserved antigenic determinant [1]. This mutation, while not resulting in complete antigenic drift detectable by cross-neutralization assays using a locally used live attenuated vaccine, highlights the potential for point mutations in VP1 to alter critical epitopes and poses a risk for future vaccine breakthrough [1].

Further evidence linking VP1 variation to virulence and antigenicity comes from studies of DHAV-1 isolates causing egg drop syndrome in adult ducks. These novel isolates harbored three specific amino acid mutations in the C-terminal variable region of VP1, distinguishing them from classical duckling-pathogenic strains [54]. Similarly, comparative pathogenicity studies of DHAV-1 isolates from Egypt identified specific amino acid substitutions in the carboxyl-terminus of VP1 (e.g., I180T, G184E, D193N, M213I) and a deletion mutation at I189 that were associated with altered pathogenicity in Pekin and Muscovy ducklings [18]. The VP1 proteins of DHAV-1 and DHAV-3 share relatively low amino acid identity, often as low as 67.6% between DHAV-3 field isolates and DHAV-1 vaccine strains, which underscores the profound antigenic differences between these serotypes and explains the lack of cross-protection [15, 17, 33].

The antigenic significance of VP1 is further emphasized by its use as a target for subunit and recombinant vaccine development. The C-terminal region of VP1 (VP1-C) from DHAV-3 has been shown to elicit significantly higher virus-specific antibody responses and neutralization titers than the full-length VP1 protein, identifying a key immunodominant domain [57]. Furthermore, a conserved linear B-cell epitope, 174PAPTST179, was identified in DHAV-1 VP1 using a nanobody, providing a specific target for serological diagnosis [45]. Recombinant viruses expressing VP1, including those based on duck enteritis virus (DEV) and Lactococcus lactis, have demonstrated the capacity to induce protective immunity against both DHAV-1 and DHAV-3, confirming the central role of VP1 in eliciting a protective host response [30, 59, 60].

Antigenic Variation and Its Impact on Vaccine Efficacy

The practical consequence of the genetic and antigenic diversity among DHAV strains is a significant challenge to vaccination programs. Comparative studies evaluating the cross-protective efficacy of current live attenuated DHAV-1 and DHAV-3 vaccines against genetically divergent wild strains have revealed crucial differences. A DHAV-1 vaccine provided only 40–60% protection against heterologous DHAV-1 field strains in ducklings without maternal-derived antibodies (MDA), whereas a DHAV-3 vaccine conferred complete protection against both homologous and heterologous DHAV-3 strains as early as 2 days post-vaccination, regardless of MDA presence [4]. This indicates that DHAV-1 vaccines exhibit limited cross-protection against genetically distant DHAV-1 variants, while DHAV-3 vaccines appear more robust within their own serotype. This disparity is likely due to greater genetic and antigenic drift within DHAV-1 field strains compared to DHAV-3 strains, necessitating the use of genotype-matched vaccines for optimal efficacy [4].

The emergence of variant strains with unique antigenic profiles is a global concern. In Egypt, the first detection of DHAV-3 in duckling flocks was reported in 2020, with isolates showing 92.4–93.7% amino acid identity to Chinese and Korean-Vietnamese DHAV-3 strains but only 74.4% identity to the locally used DHAV-1 vaccine strain [15, 17]. This low homology explains the failure of DHAV-1 vaccines to protect against DHAV-3 outbreaks, leading to significant economic losses. Similarly, a severe outbreak in Japan in 2015 was caused by a DHAV-1 strain with >96% nucleotide identity to a Chinese isolate (HB02), illustrating the transboundary spread of antigenically divergent strains [26]. The presence of multiple, co-circulating genotypes in countries like China and Egypt further complicates disease control, as ducks may require vaccination against both DHAV-1 and DHAV-3 [14, 15, 56]. The World Organisation for Animal Health (WOAH) recognizes duck viral hepatitis as a significant transboundary disease of young ducklings, underscoring the need for robust surveillance and antigenic characterization to inform vaccine strain selection [58].

Molecular Mechanisms of Attenuation and Immune Evasion

Understanding the molecular basis of virulence attenuation is critical for developing safe and efficacious live vaccines. Serial passaging of DHAV-1 and DHAV-3 in embryonated chicken eggs or duck embryos has been the classical method for attenuation. For DHAV-3, the attenuation of the HB strain to the vaccine candidate HB80 involved 80 passages, resulting in seven fixed amino acid substitutions. Two of these substitutions, one in the hypervariable region of VP1 and another in the polymerase-encoding 3D region, are strongly implicated in the loss of virulence [32]. Similarly, attenuation of the SD70 strain (from the SD parent) involved 70 passages and yielded 12 amino acid changes, with several located in structural and non-structural proteins potentially critical for viral fitness in the natural host [41]. For DHAV-3, a separate study identified that only two amino acid substitutions, Y164N in VP0 and L71I in the 2C protein, were sufficient to convert a virulent strain into an attenuated variant, directly linking these specific residues to the attenuation phenotype [46]. The attenuated strains consistently exhibit lower viral loads in liver tissues and induce a modified innate immune response in the host, characterized by altered expression of pattern recognition receptors and cytokines, compared to their virulent counterparts [19, 46].

Immune evasion mechanisms extend beyond surface antigenic variation. A novel and particularly concerning mechanism involves the transmission of DHAV-1 via exosomes. Exosomes derived from DHAV-1-infected duck embryo fibroblasts contained complete viral genomic RNA, partial viral proteins, and even intact virions. Critically, exosome-mediated infection was completely resistant to neutralization by high titers of specific antibodies, both in vitro and in vivo [10]. This represents a sophisticated mechanism for DHAV-1 to evade humoral immunity, potentially facilitating viral persistence and transmission even in the face of a strong antibody response. Additionally, the non-structural proteins of DHAV contribute to immune subversion. The 2B protein functions as a viroporin, disrupting intracellular calcium homeostasis and inducing incomplete autophagy, which may benefit viral replication while avoiding complete lysosomal degradation [12]. The 3C protease mediates the cleavage of host poly(A)-binding protein (PABP), a key factor in cellular translation, thereby contributing to host translation shutoff and favoring viral protein synthesis [21]. The 3D polymerase has also been shown to localize to the nucleus, where it may play a role in the shutoff of host cell transcription [29]. At the host level, the cellular protein PLAC8 is significantly upregulated during DHAV-1 infection and facilitates viral replication by suppressing the TLR7-MyD88-dependent signaling pathway, thereby dampening the innate antiviral response [8]. These molecular interactions, combined with host genetic factors like the expression of IFITM1 and NOD1 that influence resistance or susceptibility to DHAV-3, create a complex host-pathogen interface that drives ongoing molecular and antigenic evolution of DHAV strains [36, 37].

Diagnostic Approaches for Duck Hepatitis A Virus

The accurate and timely diagnosis of Duck Hepatitis A Virus (DHAV) infection is paramount for effective disease management, outbreak control, and the implementation of strategic vaccination programs in the global duck industry. Given the acute, highly lethal nature of duck viral hepatitis (DVH), particularly in ducklings under three weeks of age, diagnostic approaches must be rapid, sensitive, and capable of differentiating between the three serotypes (DHAV-1, DHAV-2, and DHAV-3) and other pathogens that present with similar clinical and pathological manifestations, such as novel duck reovirus (NDRV), duck tembusu virus (DTMUV), and duck astrovirus [51-53]. The diagnostic landscape has evolved considerably from classical virological methods to sophisticated molecular, serological, and point-of-care technologies, each with distinct advantages and limitations dictated by the specific clinical context, available laboratory infrastructure, and the need for genotype-level discrimination.

Traditional Virus Isolation and Electron Microscopy

Historically, the definitive diagnosis of DHAV relied heavily on virus isolation in embryonated duck eggs (EDEs) or specific-pathogen-free (SPF) chicken embryos, coupled with characteristic histopathological and ultrastructural observations. This classical approach remains a cornerstone for the initial characterization of field strains and the generation of high-titer virus stocks for vaccine development and research. For virus isolation, samples from liver, spleen, or kidney are homogenized, clarified, and inoculated into the allantoic cavity of 9-to-11-day-old embryonated eggs. A hallmark of DHAV-1 infection is the development of a distinctive greenish discoloration of the allantoic fluid, accompanied by generalized hepatitis, dwarfism, stunting, and embryonic mortality within three to seven days post-inoculation [1, 13, 18]. Gross pathological changes in the embryos include subcutaneous hemorrhages and necrotic greenish-yellow foci on the liver surface [18, 23]. While DHAV-1 and DHAV-3 can both be isolated using this method, subtle differences in the timing and severity of embryonic lesions may be observed, though these are not reliable for serotyping. The utility of this method, however, is constrained by its long turnaround time (typically 5–7 days), the requirement for a continuous supply of embryonated eggs, and the potential for non-specific mortality. Furthermore, the adaptation of DHAV strains to cell culture, particularly in duck embryo fibroblasts (DEFs), has been notoriously difficult due to the inhibitory effects of fetal calf serum (FCS) on viral replication [47, 50]. Research has demonstrated that FCS exerts a direct inhibitory effect on DHAV-1 and DHAV-3 at the stages of adsorption, replication, and release, whereas the use of chicken serum (CS) in maintenance medium facilitates productive, cytocidal infection and plaque formation [47, 50]. This biological nuance underscores the critical importance of standardized cell culture conditions for diagnostic virus isolation and highlights the mechanistic complexity of host-virus interactions. Transmission electron microscopy (TEM) can confirm the presence of picornavirus-like particles (approximately 25–30 nm in diameter) in negative-stained preparations from allantoic fluid or tissue homogenates, providing a rapid morphological identification but lacking serotype specificity. Despite their foundational role, these traditional methods are increasingly being supplanted by molecular techniques in routine diagnostic workflows due to the latter’s superior speed, sensitivity, and throughput.

Molecular Diagnostic Approaches: From Conventional to Next-Generation

The advent of reverse transcription polymerase chain reaction (RT-PCR) has revolutionized the diagnosis of DHAV, enabling the rapid detection of viral nucleic acids with exquisite sensitivity and specificity. Conventional RT-PCR, targeting conserved regions of the 5′ untranslated region (5′ UTR), the VP1 capsid gene, or the 3D polymerase gene, has been widely employed for the initial screening of clinical samples and for epidemiological surveillance [5, 17, 26, 56]. The 5′ UTR is a highly conserved region, making it an ideal target for pan-DHAV detection assays [33, 56]. However, the differentiation of DHAV-1 from DHAV-3 requires genotype-specific amplification, which is most effectively achieved by targeting the VP1 gene due to its considerable sequence divergence between serotypes [4, 14, 56, 65]. A landmark advancement in this domain was the development of a one-tube duplex RT-PCR assay capable of simultaneously detecting and differentiating DHAV-1 and DHAV-3 in a single reaction [56, 65]. This method employs a universal forward primer and genotype-specific reverse primers, yielding amplicons of distinct sizes that can be resolved by agarose gel electrophoresis. This approach has been instrumental in revealing the cocirculation of both serotypes and the increasing prevalence of DHAV-3 in China and Egypt, providing critical data for vaccine strain selection [5, 14, 15, 56]. The assay’s ability to discriminate between wild-type and vaccine strains based on VP1 sequence analysis further enhances its utility for outbreak investigations and post-vaccination surveillance [65].

Real-time quantitative RT-PCR (RT-qPCR) has further refined molecular diagnostics by providing quantitative viral load data, which is crucial for understanding pathogenesis, monitoring disease progression, and evaluating vaccine efficacy. TaqMan probe-based multiplex RT-qPCR assays have been developed for the simultaneous detection of DHAV-1, DHAV-3, and other economically significant duck pathogens such as NDRV and DTMUV, addressing the growing challenge of mixed infections [52]. These assays demonstrate high analytical sensitivity, with detection limits in the range of 10¹ to 10² copies/μL, and exhibit excellent linearity (R² > 0.99) and amplification efficiencies (80–100%) [52]. Importantly, they show no cross-reactivity with other common duck viruses, including duck enteritis virus (DEV), muscovy duck parvovirus (MDPV), and avian influenza virus (AIV), ensuring diagnostic specificity [52]. The application of these multiplex assays in field surveillance has revealed complex co-infection patterns, such as DHAV-3 and DTMUV co-infections in up to 5.58% of clinical samples, highlighting the necessity for comprehensive diagnostic panels [52]. Similarly, SYBR Green I-based real-time PCR assays offer a cost-effective alternative for the simultaneous detection of DHAV-1 and duck astrovirus type 3 (DAstV-3), another pathogen that causes hepatitis in ducklings [53]. These assays can detect as few as 7.34 × 10¹ copies/μL for DHAV-1, providing rapid and reliable results for differential diagnosis [53].

For field-based and resource-limited settings, isothermal amplification technologies have emerged as powerful alternatives to conventional PCR, circumventing the need for expensive thermocyclers. A reverse transcription-insulated isothermal PCR (RT-iiPCR) assay, utilizing the portable POCKIT™ system, has been successfully developed for the on-site detection of DHAV-3 [64]. Targeting the VP3 gene, this method achieves a detection limit of 3.85 × 10¹ copies/μL, with 100% analytical sensitivity and specificity when tested on clinical liver samples, and demonstrates 97.5% agreement with standard RT-qPCR [64]. The entire process can be completed in under one hour, making it highly suitable for rapid outbreak response and quarantine decisions. More recently, the integration of recombinase polymerase amplification (RPA) with CRISPR-Cas12a/Cas13a systems has resulted in a paradigm shift for point-of-care diagnostics. The RPA-CRISPR one-pot strategy (DRCFS) and its lateral flow-based counterpart (DRC-LFA) enable the simultaneous detection of DHAV-3 and NDRV with extraordinary sensitivity, achieving limits of 10⁰ and 10¹ copies/μL, respectively, within just 35 minutes [51]. This method eliminates the need for complex instrumentation, as results can be read visually on a lateral flow strip, and the single-tube, closed-system design minimizes the risk of aerosol contamination. These features render the RPA-CRISPR approach invaluable for on-site virus detection in duck farms, where early and accurate diagnosis can directly inform biosecurity measures and reduce economic losses.

Serological and Immunological Assays

Serological methods complement nucleic acid-based detection by providing evidence of past or current infection and assessing herd immunity. Enzyme-linked immunosorbent assays (ELISAs) are the mainstay of serological diagnosis. Indirect ELISAs based on recombinant structural proteins, particularly VP1, are commonly used to detect DHAV-specific antibodies [57, 59, 60, 62]. The VP1 protein contains critical neutralizing epitopes, and VP1-specific antibody titers correlate well with protective immunity [45, 57]. An alternative approach utilizes the non-structural protein 3A as a coating antigen, which has the advantage of differentiating infected from vaccinated animals (DIVA) in the context of live attenuated vaccine use, as 3A antibodies are generated only during active viral replication [63]. The 3A-ELISA demonstrates high sensitivity (titer of 1:1280) and specificity, with a concordance rate of 92.7% compared to an ELISA based on whole DHAV-1 particles, and shows no cross-reactivity with antibodies against other duck pathogens [63]. Virus neutralization (VN) tests remain the gold standard for assessing functional antibody responses and antigenic relatedness between field and vaccine strains. Cross-neutralization assays, using panels of monospecific antisera, have been instrumental in detecting antigenic drift and escape mutations, such as the S178Y substitution in the VP1 protein of DHAV-1, which can affect neutralization profiles and potentially compromise vaccine efficacy [1, 4]. These serological tools are critical for evaluating the effectiveness of vaccination programs and for guiding the selection of appropriate vaccine strains in the face of emerging genetic variants [4, 61]. The development of nanobodies, such as Nb25 which recognizes a conserved linear B-cell epitope (¹⁷⁴PAPTST¹⁷⁹) on VP1, offers a novel avenue for serologic diagnosis, providing highly specific reagents that can be produced recombinantly and engineered for various diagnostic platforms [45].

Emerging Diagnostic Technologies and Genomic Surveillance

The application of next-generation sequencing (NGS) and metagenomic analysis represents the most comprehensive diagnostic approach, enabling the unbiased detection of known and novel pathogens, as well as the detailed characterization of viral genomes. Metagenomic NGS (m-NGS) has been pivotal in identifying the first complete genome of DHAV-3 in Egypt and in discovering co-infections with novel duck astroviruses, revealing complex viral communities that would be missed by targeted assays [1, 3]. Whole-genome sequencing via NGS facilitates high-resolution phylogenetic and phylogeographic analyses, tracking the global dissemination and evolutionary dynamics of DHAV strains, including the identification of recombination hotspots and the emergence of intra- and intergenotype recombinants [9, 11, 13]. For instance, complete genome analysis of an Egyptian DHAV-1 isolate revealed 99.9% identity with a Hungarian strain from 2004, suggesting international transmission links [1]. Furthermore, NGS data underpin the design of more robust and broadly reactive diagnostic primers and probes, ensuring that molecular assays remain effective against evolving viral populations. The integration of these advanced genomic surveillance tools into routine diagnostic workflows, as recommended by the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO), is essential for the proactive management of DHAV, a pathogen of critical economic importance to the global duck farming sector.

Immune Evasion and Vaccine Efficacy Against Duck Hepatitis A Virus

The interplay between Duck Hepatitis A Virus (DHAV) and the host immune system is a complex and dynamic battlefield that dictates the outcome of infection, from rapid mortality in susceptible ducklings to persistent, asymptomatic carriage in mature ducks. The virus has evolved a sophisticated arsenal of immune evasion strategies that directly impact the efficacy of vaccination programs, which remain the cornerstone of disease control. Understanding these mechanisms is not merely an academic exercise; it is a critical prerequisite for designing next-generation vaccines capable of overcoming the genetic and antigenic drift that threatens current prophylactic measures. This section provides an exhaustive analysis of the molecular mechanisms of immune evasion employed by DHAV and critically evaluates the efficacy of existing vaccines in the face of an evolving viral landscape.

Molecular Mechanisms of Innate Immune Evasion

The innate immune system represents the first line of defense, and DHAV has developed multiple strategies to subvert this early warning network. A primary target is the pattern recognition receptor (PRR) signaling cascade, which is essential for detecting viral invasion and initiating the interferon (IFN) response.

Subversion of TLR and RLR Signaling

One of the most well-characterized evasion strategies involves the manipulation of Toll-like receptor (TLR) and RIG-I-like receptor (RLR) pathways. Research has demonstrated that the host protein placenta-specific 8 (PLAC8) is co-opted by DHAV-1 to facilitate infection. PLAC8 expression is significantly induced upon DHAV-1 infection, and it acts by suppressing the expression of TLR7, a key sensor for single-stranded RNA viruses. This suppression leads to a downstream decrease in myeloid differentiation primary response gene 88 (MyD88) and nuclear factor kappa-B (NF-κB) activation, ultimately resulting in reduced levels of type I interferon and interleukin-6 (IL-6) [8]. This represents a clear example of the virus hijacking a host protein to dampen the antiviral state. Concurrently, the virus's impact on the RLR pathway is profound. Transcriptomic analyses of Pekin ducks with differential susceptibility to DHAV-3 reveal that susceptible lines exhibit significantly higher expression of RIG-I and MDA5 compared to resistant lines, yet this heightened PRR expression correlates with severe pathology and high viral loads, suggesting that the virus may actively dysregulate these pathways to trigger a maladaptive, hyperinflammatory response rather than a protective one [24]. This is further supported by proteomics data showing that DHAV-3 infection strongly activates RIG-I-like, Toll-like, and NOD-like receptor signaling pathways, but the net effect is an exacerbation of liver damage rather than viral clearance [42].

Interference with Interferon-Stimulated Genes (ISGs)

Beyond blocking interferon induction, DHAV also interferes with the effector functions of interferon-stimulated genes. The interferon-induced transmembrane protein 1 (IFITM1) is a potent antiviral factor that restricts the entry of a wide range of viruses. In Pekin ducks selectively bred for resistance to DHAV-3, IFITM1 was identified as a key candidate gene associated with resistance. In susceptible ducks, DHAV-3 infection leads to a dysregulation of the cell cycle, which is linked to altered IFITM1 expression levels [36]. This suggests that the virus may modulate IFITM1 activity to create a more permissive cellular environment for replication. Furthermore, the expression of duck IFIT5, another member of the IFIT family, is rapidly and strongly induced following DHAV-3 infection, and its expression level is positively correlated with viral load [68]. While IFIT5 is part of the antiviral response, its correlation with viral load implies that DHAV-3 may either be resistant to its effects or actively exploit its presence for replication, a phenomenon observed with other viruses.

Manipulation of the Cytokine Storm and Apoptosis

A hallmark of virulent DHAV-1 infection is the induction of a severe cytokine storm, which is primarily responsible for the rapid death of ducklings. The virulent CH strain of DHAV-1 triggers a massive, uncontrolled release of pro-inflammatory cytokines in the liver, leading to severe hemorrhagic lesions and rapid mortality. In stark contrast, the attenuated CH60 vaccine strain induces a much milder, controlled immune response without causing a cytokine storm [19]. This differential induction of inflammation is a critical determinant of virulence. The virus also actively manipulates programmed cell death. The structural protein VP3 of DHAV-1 has been shown to mediate host cell apoptosis via the mitochondrial intrinsic pathway, upregulating pro-apoptotic factors like Bak, Cyt c, and Apaf-1, and activating caspase-3, -8, and -9 [44]. While apoptosis can be a host defense mechanism, DHAV-1 appears to use it to facilitate viral dissemination and cause tissue damage. Conversely, the 2B protein of DHAV-1, which functions as a viroporin, induces incomplete autophagy. It elevates intracellular Ca²⁺ levels and increases autophagosome formation, but the autophagic flux is blocked, preventing the fusion of autophagosomes with lysosomes. This incomplete autophagy likely provides a membranous scaffold for viral replication complexes while avoiding the degradative consequences of complete autophagy [12].

Adaptive Immune Evasion and Viral Persistence

While innate immunity is crucial for early control, the adaptive immune response is essential for long-term protection and viral clearance. DHAV has evolved mechanisms to evade both humoral and cell-mediated immunity, contributing to its ability to establish persistent infections.

Exosome-Mediated Evasion of Neutralizing Antibodies

A groundbreaking discovery in DHAV-1 immunology is the virus's ability to hijack the host's exosomal pathway for intercellular transmission. DHAV-1 has been shown to incorporate its complete genomic RNA, partial viral proteins, and even intact virions into exosomes secreted from infected duck embryo fibroblasts (DEFs). These exosomes can then deliver infectious virus to new cells. Critically, this exosome-mediated infection is resistant to neutralization by high titers of DHAV-1-specific neutralizing antibodies. While free virus particles are effectively neutralized, the exosome-encapsulated virus is shielded from antibody recognition, allowing it to establish a productive infection in the presence of a robust humoral immune response [10]. This represents a potent and previously unrecognized immune evasion mechanism that could explain vaccine breakthroughs and the establishment of persistent infections.

Lymphoid Tropism and Persistent Infection

DHAV-1 possesses a remarkable tropism for lymphoid tissues, which is a key strategy for immune evasion and persistence. The virus can infect and replicate productively in lymphoid organs such as the thymus, spleen, and bursa of Fabricius, persisting for over six months in mature ducks. This lymphoid replication contributes significantly to viremia. Critically, DHAV-1 infection in these organs skews the immune response towards a Th2-dominant profile, characterized by consistently higher levels of IL-4 compared to IL-2 and IFN-γ. This shift away from a Th1-mediated cytotoxic T lymphocyte (CTL) response, which is crucial for clearing intracellular viruses, allows the virus to evade cell-mediated immunity. Furthermore, the virus dysregulates the expression of chemokines (CCL19, CCL21) and major histocompatibility complex (MHC) molecules, which are essential for T cell homing and antigen presentation, thereby further impairing the development of an effective adaptive immune response [48].

Translational Shutoff and Host Protein Cleavage

DHAV employs a "scorched earth" tactic by shutting off host cell protein synthesis to prioritize viral translation. DHAV-1 infection induces phosphorylation of eukaryotic initiation factor 2 alpha (eIF2α) via the kinases PERK and GCN2, leading to a global inhibition of cellular translation. Notably, the role of GCN2 in this process is unique among picornaviruses. This translational shutoff is dependent on eIF2α phosphorylation, and when this phosphorylation is inhibited, cellular translation is restored [39]. To further cripple the host, the viral 3C protease directly cleaves the poly(A)-binding protein (PABP), a critical factor for host mRNA translation and stability. The cleavage of PABP generates specific fragments and is a strategy to manipulate viral replication, as knockdown of PABP inhibits viral RNA production [21]. This multi-pronged attack on the host translational machinery ensures that the cellular resources are diverted exclusively to viral replication, effectively starving the host cell of the ability to mount an effective immune response.

Vaccine Efficacy and the Challenge of Antigenic Diversity

The efficacy of current vaccines is inextricably linked to the virus's ability to evade immunity. While vaccines have been instrumental in controlling DHAV, the emergence of new genotypes and antigenic variants poses a persistent threat.

Cross-Protection Between DHAV-1 and DHAV-3

A critical challenge in DHAV vaccinology is the lack of robust cross-protection between serotypes. A comprehensive meta-analysis of studies in mainland China from 2009 to 2021 confirmed that while DHAV vaccines are highly effective, their protective effect is largely serotype-specific. The widespread use of DHAV-1 vaccines has successfully driven down the incidence of DHAV-1, but this has been accompanied by a significant increase in DHAV-3 prevalence, which now accounts for a higher proportion of clinical cases [5]. This epidemiological shift is a direct consequence of the lack of cross-protection. Experimental challenge studies have quantified this limitation. In ducklings without maternal-derived antibodies (MDA), a DHAV-1 vaccine provided only 40-60% survival against heterologous DHAV-1 strains, whereas the DHAV-3 vaccine conferred complete protection against both homologous and heterologous DHAV-3 strains as early as 2 days post-vaccination [4]. This demonstrates that while DHAV-3 vaccines appear to offer broader intra-serotype protection, the inter-serotype gap remains a major vulnerability.

Genetic and Antigenic Drift in Field Strains

The continuous evolution of DHAV through mutation and recombination generates field strains that can escape vaccine-induced immunity. Phylogenetic analyses have revealed that DHAV-1 and DHAV-3 field strains are increasingly classified into different genotypes compared to the older vaccine strains [4]. In Egypt, a DHAV-1 isolate (Du/Egy/Benha/2020) was found to harbor a unique escape mutation, S178Y, in a conserved antigenic determinant on the VP1 protein. Although cross-neutralization assays showed minimal antigenic variation, the presence of this mutation signals a potential for immune evasion that could compromise vaccine efficacy over time [1]. Similarly, the emergence of DHAV-3 in Egypt, which is genetically distinct from the locally used DHAV-1 vaccine, has been linked to outbreaks in vaccinated flocks, underscoring the urgent need for genotype-matched vaccines [15, 17]. The VP1 gene, which is the primary target for neutralizing antibodies, is a hotspot for such variation. Studies have identified multiple hypervariable regions (HVRs) in VP1, and mutations in the C-terminus of VP1, such as I180T, G184E, D193N, and M213I, have been associated with altered pathogenicity and potential antigenic changes [18, 23].

Impact of Maternal-Derived Antibodies (MDA)

The presence of MDA is a double-edged sword in DHAV vaccination. While MDA provides crucial passive protection to young ducklings, it can also interfere with the efficacy of live attenuated vaccines administered at an early age. A comparative study demonstrated that in ducklings with MDA, the DHAV-1 vaccine provided full protection against heterologous strains only when an additional booster vaccination was given to day-old ducklings. In contrast, the DHAV-3 vaccine conferred complete protection regardless of MDA presence [4]. This highlights the importance of optimizing vaccination schedules based on the serotype and the MDA status of the flock. The meta-analysis further revealed that the immune protective effect of vaccines can differ between small-scale experimental conditions and large-scale clinical conditions, likely due to non-standard vaccination practices and environmental factors that can influence MDA levels and immune responses [61].

Development of Next-Generation Vaccines

In response to the limitations of traditional live attenuated vaccines, significant efforts are underway to develop novel vaccine platforms that can provide broader, safer, and more durable protection.

Recombinant Vector Vaccines: The use of duck enteritis virus (DEV) as a bivalent vector has shown exceptional promise. Recombinant DEV expressing the VP1 genes of both DHAV-1 and DHAV-3 (rC-KCE-2VP1) induced potent humoral and cellular immune responses and provided complete protection against lethal challenge with both serotypes, with protection achieved as early as 3 days post-vaccination [30]. Similarly, DEV recombinants expressing the P1 and 3C genes of DHAV-3 have demonstrated complete protection against DHAV-3 infection and lethal DEV challenge [66]. These vectored vaccines offer the advantage of rapid, broad-spectrum protection and the potential to differentiate infected from vaccinated animals (DIVA).

Subunit and Recombinant Protein Vaccines: Subunit vaccines offer a safer alternative to live vaccines. A truncated version of the DHAV-3 VP1 protein (VP1-C) expressed in E. coli, when combined with a flagellin adjuvant (nFliC), elicited high levels of virus-specific antibodies, T cell proliferation, and a Th1-biased cytokine response, providing 75% protection against lethal challenge [57]. Other novel approaches include the use of avian adeno-associated virus (AAAV) vectors to deliver the VP1 or VP3 genes, which induced protective immunity comparable to commercial attenuated vaccines [62, 67].

Mucosal and Probiotic Vaccines: Oral vaccines using recombinant Lactococcus lactis expressing the VP1 protein of DHAV-1 or DHAV-3 have been developed to induce mucosal and systemic immunity. These probiotic-based vaccines successfully induced specific anti-VP1 IgG and mucosal sIgA antibodies, along with a balanced Th1/Th2 cytokine response, and effectively protected ducklings against natural infection [59, 60]. This approach offers a needle-free, stress-free vaccination strategy that is particularly suited for large-scale poultry operations.

Genetic Resistance as a Complementary Strategy: Beyond vaccination, selective breeding for genetic resistance offers a powerful, long-term strategy for disease control. Through artificial selection, researchers have developed a Pekin duck line (Z8) that is highly resistant to DHAV-3, with mortality rates reduced from 59.2% to 7.8% over four generations. This resistance is associated with specific genetic markers, including mutations in the CRHR2 gene, and a controlled, non-inflammatory immune response characterized by lower viral loads and reduced expression of pro-inflammatory cytokines [24, 34]. Integrating such resistant lines into breeding programs could significantly reduce reliance on vaccines and mitigate the impact of emerging variants.

Emerging Detection Technologies and Future Directions for DHAV Control

The persistent economic burden inflicted by Duck Hepatitis A Virus (DHAV) on global duck production necessitates a paradigm shift in both diagnostic capabilities and long-term control strategies. The virus’s high morbidity and mortality in young ducklings, coupled with the emergence of new genotypes (particularly DHAV-3) and the increasing frequency of mixed infections with pathogens such as novel duck reovirus (NDRV) and duck astrovirus, demand diagnostic tools that transcend the limitations of conventional methods [2, 3, 52]. Concurrently, the evolution of vaccine technologies, a deeper understanding of host genetics, and the exploration of novel antiviral agents are reshaping the landscape of DHAV control. This section provides an exhaustive analysis of these emerging technologies and the future directions they illuminate for managing DHAV.

The Next Generation of Molecular Diagnostics: From Lab Bench to Point-of-Care

Conventional RT-PCR and virus isolation, while foundational, are often too slow or resource-intensive for effective outbreak management. The field is now witnessing a surge in technologies designed for speed, sensitivity, and field deployability.

CRISPR-based Diagnostics: The Vanguard of Rapid, On-Site Detection

The integration of Recombinase Polymerase Amplification (RPA) with CRISPR-Cas systems represents a transformative leap forward. Zhang et al. [51] developed a one-pot RPA-CRISPR Cas12a/Cas13a strategy (DRCFS) for the simultaneous detection of DHAV-3 and NDRV. This method is a masterclass in engineering around practical constraints: by combining RPA and CRISPR reactions in a single, closed tube, it elegantly solves the problem of aerosol contamination, a major bane of molecular diagnostics. The sensitivity of this platform is remarkable, achieving a limit of detection of 100 copies/μL with fluorescence readout. The researchers further extended this concept to a lateral flow analysis platform (DRC-LFA), which is a game-changer for point-of-care testing. The DRC-LFA not only achieved a lower detection limit of 101 copies/μL within 35 minutes but also eliminated the need for complex, costly instrumentation, allowing for direct visual interpretation of results [51]. This dual-modality approach (fluorescence and lateral flow) provides flexibility for different laboratory and field settings. For a pathogen like DHAV-3, which is often found in co-infections, the ability to multiplex, simultaneously detecting two or more pathogens in a single reaction, provides an invaluable epidemiological and clinical advantage, enabling rapid differential diagnosis.

The Rise of High-Throughput and Multiplexed Real-Time Assays

While CRISPR-based tools excel in speed and portability, multiplex real-time RT-qPCR remains the gold standard for high-throughput, quantitative surveillance. The development of a TaqMan probe-based multiplex RT-qPCR for the simultaneous detection of DTMUV, NDRV, DHAV-1, and DHAV-3 by Qiu et al. [52] is a stellar example of modern diagnostic refinement. The assay demonstrates excellent analytical performance, with detection limits ranging from 60.3 to 188 copies/μL and no cross-reactivity with other common duck pathogens like DEV, MDPV, or AIV [52]. The high reproducibility (CVs below 10%) and robust amplification efficiencies (80-100%) make it a reliable tool for large-scale surveillance programs. The application of this method to 215 clinical samples revealed a significant prevalence of co-infections, notably DHAV-3 and DTMUV, which are often missed by single-plex assays. This highlights a critical future direction: the routine use of such multiplex panels will be essential for understanding the true complexity of field outbreaks, where multiple viral agents often act in concert to produce severe disease [2, 52]. Similarly, the development of a duplex SYBR Green I-based qPCR for DHAV-1 and duck astrovirus-3 (DAstV-3) by Li et al. [53] addresses the diagnostic challenge posed by their similar clinical presentations, offering a cost-effective alternative for differential diagnosis.

Isothermal and Streamlined PCR for the Field

Adapting PCR technology for field use has led to innovations like the reverse transcription-insulated isothermal PCR (RT-iiPCR) based on the POCKIT™ system. Ren et al. [64] developed a rapid RT-iiPCR assay for DHAV-3 targeting the VP3 gene. The system’s portability and speed, coupled with a detection limit of 3.85 × 10¹ copies/μL and 100% sensitivity and specificity relative to rRT-PCR, make it an excellent candidate for on-site diagnosis at farms or quarantine points. The simplicity of the platform, requiring minimal user training, democratizes molecular diagnostics, moving capacity away from centralized laboratories.

Furthermore, the development of a one-tube RT-PCR for simultaneous detection and genotyping of DHAV-1 and DHAV-3 by Chen et al. [56] provides a streamlined approach for routine surveillance. By designing universal and type-specific primers in a single reaction, this method can differentiate between the two subtypes based on amplicon size, offering a rapid and cost-effective tool for epidemiological screening. The ability to simultaneously detect and sequence the VP1 gene, as demonstrated by Wen et al. [65], adds another layer of utility, linking diagnosis directly with molecular epidemiological tracking of emerging variants.

Future Directions in DHAV Control: Beyond Traditional Vaccination

While diagnostics are crucial for intervention, long-term control hinges on effective prevention and the ability to counter viral evolution. The future of DHAV control is being shaped by innovations in vaccinology, a deeper exploitation of host genetics, and the search for novel therapeutics.

Revolutionizing Vaccinology: Recombinant Vectors and Subunit Platforms

Live attenuated vaccines have been the cornerstone of DHAV control, but they carry inherent risks of reversion to virulence and limited cross-protection against divergent strains [1, 4, 6]. The field is moving toward safer, more versatile platforms.

1. Recombinant Viral Vectors: The use of duck enteritis virus (DEV) as a bivalent vector is particularly promising. Zou et al. [30] engineered a DEV recombinant (rC-KCE-2VP1) expressing VP1 proteins from both DHAV-1 and DHAV-3. This single-dose vaccine provided complete protection against lethal challenge with both subtypes, highlighting its power as a bivalent tool. The rapid onset of immunity, as early as 3 days post-vaccination, is a critical advantage for controlling fast-spreading outbreaks. Further refinement by Yang et al. [66] using a fosmid-based rescue system to generate rDEV expressing the P1 and 3C genes of DHAV-3 also yielded complete protection, underscoring the robustness of this vector platform. Similarly, avian adeno-associated virus (AAAV) vectors have shown efficacy, expressing DHAV-1 VP1 [62] and VP3 [67] proteins to induce protective immunity. These vectored vaccines are stable, induce both humoral and cellular immunity, and can be engineered to express antigens from multiple serotypes, directly addressing the issue of antigenic diversity [4].

2. Bacterium-based Subunit Vaccines: The use of food-grade Lactococcus lactis as an oral delivery vehicle for DHAV antigens represents a safe and cost-effective approach. Zhang et al. [59] constructed a recombinant L. lactis secreting the VP1 fusion protein of DHAV-1, which successfully induced specific IgG and mucosal sIgA antibodies, as well as a balanced Th1/Th2 cytokine response, protecting ducklings from natural infection. Song et al. [60] achieved similar success for DHAV-3 using a nisin-controlled expression system. This platform is particularly attractive for large-scale poultry operations, as it can be administered orally via feed or water, eliminating the stress and labor associated with individual injections.

3. Subunit Vaccines and Adjuvants: The quest for precisely defined, non-infectious antigens is exemplified by the work of Truong and Cheng [57], who developed a subunit vaccine based on the C-terminal region of the DHAV-3 VP1 protein (VP1-C) combined with a truncated flagellin adjuvant (nFliC). This formulation elicited a robust neutralizing antibody response and provided 75% protection against lethal challenge, outperforming the full-length VP1 antigen. This work demonstrates the importance of antigen design, focusing on critical, immunogenic regions, and the strategic use of adjuvants to tailor the immune response (in this case, a TH-1 bias) for optimal protection.

Harnessing Host Genetics: Breeding for Resistance and Understanding Susceptibility

A revolutionary, complementary approach to vaccination is the genetic selection of DHAV-resistant duck lines. The work by Liang et al. [24, 34, 36, 37, 43] on Pekin ducks is groundbreaking. By using artificial selection based on genealogical and phenotypic observations, they developed a highly resistant line (Z8) and a highly susceptible line (Z7) to DHAV-3. The results are striking: mortality in the resistant line dropped from 59.2% to 7.8% over four generations, while the susceptible line’s mortality rose to 81% [34]. Genome-wide analysis identified key genes associated with this differential resistance.

• NOD1 and IFITM1 as Key Susceptibility Factors: The NOD1 gene, a pattern recognition receptor, was strongly associated with susceptibility, with higher expression in the susceptible flock [37]. Suppression of NOD1 reduced DHAV-3 replication in hepatocytes, directly implicating it in the pathogenic pathway. Similarly, transcriptomic analysis revealed that IFITM1 expression was tightly linked to resistance, and its conserved regions affected the cell cycle of infected fibroblasts [36]. This suggests that resistant birds may mount a more effective cell cycle arrest response that limits viral replication.

• Metabolic and Immune Pathway Insights: The resistant line (Z8) showed a dramatic suppression of viral replication in the liver and a dampened inflammatory response, with significantly lower levels of serum biochemical markers (ALT, AST) and cytokines (IL-2, IL-6, IFN-α, IFN-γ) compared to the susceptible line [24]. Further transcriptomic analysis revealed that DHAV-3 infection causes severe glucose metabolic abnormalities in susceptible ducks, driven by cytokines that activate the PI3K-AKT and JAK-STAT pathways, leading to downregulation of gluconeogenic enzymes [43]. This indicates that the host's metabolic state is not merely a consequence of infection but an integral part of the pathogenic mechanism.

These findings provide a roadmap for marker-assisted selection. Breeding ducks for a "resistant" genotype, characterized by specific alleles in genes like CRHR2 (identified in the resistant Z8 line) [34], lower constitutive expression of NOD1 [37], and a more controlled inflammatory response, could lead to flocks that are inherently less susceptible to DHAV. This represents a sustainable, long-term control strategy that reduces reliance on vaccines and antivirals.

Exploiting Viral Vulnerabilities: Antivirals and Immune Modulation

The rapid death of ducklings from DHAV, often linked to a devastating "cytokine storm" [19], has spurred research into therapeutic interventions.

1. Targeting Viral Replication and Host Translation: The 3C protease of DHAV is a prime target. Sun et al. [21] demonstrated that the 3C protease cleaves the host's poly(A)-binding protein (PABP), a critical factor for host mRNA translation. Inhibiting this specific cleavage event could cripple the virus's ability to subvert the host cell's machinery. Furthermore, the identification of a functional nuclear localization signal (NLS) in the 3D polymerase (3Dpol) [29] offers another target; preventing the polymerase from entering the nucleus could block its role in shutting off host transcription.

2. Natural Product Antivirals: The use of plant-derived compounds is gaining traction. Baicalin, a flavonoid from Scutellaria baicalensis, has shown significant antiviral activity against DHAV-1. Its mechanism is multi-faceted: it protects against mitochondrial dysfunction by activating the Nrf2/ARE antioxidant signaling pathway, thereby reducing oxidative stress and preserving liver function [69]. Chen et al. [70] enhanced baicalin's bioavailability by creating a phospholipid complex (BAPC), which showed superior antiviral and immune-enhancing effects both in vitro and in vivo, inhibiting viral adsorption, replication, and release. Similarly, a nanoemulsion of turmeric and black pepper oil was shown to attenuate the DHAV-1-induced cytokine storm, reducing viral RNA loads and mortality [7]. These studies validate the concept of using nutraceuticals as supportive or therapeutic agents.

3. Modulating Autophagy and Exosome-Mediated Spread: The virus’s life cycle itself offers intervention points. The 2B protein of DHAV-1 functions as a viroporin, disrupting calcium homeostasis and inducing incomplete autophagy, which is hijacked to support viral replication [12]. Phosphorylated Codonopsis pilosula polysaccharide (pCPPS) was shown to inhibit DHAV-1 replication by interfering with autophagosome formation [38]. This demonstrates that targeting the virus's manipulation of host cell processes like autophagy is a viable antiviral strategy. Furthermore, the discovery that DHAV-1 can be transmitted via exosomes, which are resistant to neutralizing antibodies [10], reveals a sophisticated immune evasion mechanism. Future research must explore strategies to block this exosome-mediated pathway to enhance the efficacy of both vaccines and antiviral therapies.

In conclusion, the future of DHAV control is not a single solution but a multi-pronged, integrated strategy. Point-of-care diagnostics like CRISPR-LFA will empower rapid, informed decision-making on farms. Vaccination will evolve away from live attenuated strains toward safe, multivalent recombinant vectors and subunit vaccines that provide robust cross-protection. Concurrently, selective breeding for genetic resistance will build inherent flock resilience, while targeted antiviral therapies and immune modulators will provide therapeutic options to mitigate outbreaks. The epidemiological lessons are clear: continuous genomic surveillance of circulating strains, particularly through whole-genome sequencing, is essential to detect emerging variants and antigenic shifts that could undermine vaccine efficacy [1, 9, 11]. The integration of these advanced detection technologies with next-generation prophylactics and therapeutics will define the next era of DHAV management.

References

[1] Moharam I, Abaza MA, Khalil NW, El-Nahas E, El-Habbaa A, Najar F, et al.. Complete genome sequencing, molecular and antigenic characterization of duck hepatitis A virus type 1 isolated in Benha, Egypt. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-05010-5

[2] Zhao S, Wu B, Wang Q, Wei X, Liu X, Tang Y, et al.. Advances in the Duck Hepatitis A virus and lessons learned from those in recent years.. Microbial Pathogenesis. 2024. DOI: https://doi.org/10.1016/j.micpath.2024.107018

[3] El-Mayet FS, Moharam I, El-Nahas E, El-Habbaa A, Najar F, Stayton E, et al.. First identification of concurrent infections with novel emerging duck astrovirus and duck hepatitis A virus type 3 (DHAV-3) in ducklings in Egypt using metagenomic next-generation sequencing (m-NGS).. Avian Pathology. 2025. DOI: https://doi.org/10.1080/03079457.2025.2581279

[4] Kim S, Yu C, Park J, Ma X, Zhu T, Li Y, et al.. The Impact of Genetic Variation on Duck Hepatitis A Virus (DHAV) Vaccine Efficacy: A Comparative Study of DHAV-1 and DHAV-3 Against Emerging Variant Strains. Vaccines. 2024. DOI: https://doi.org/10.3390/vaccines12121416

[5] Zhou S, Li S, Wang Y, Li X, Zhang T. Duck hepatitis A virus prevalence in mainland China between 2009 and 2021: A systematic review and meta-analysis.. Preventive Veterinary Medicine. 2022. DOI: https://doi.org/10.1016/j.prevetmed.2022.105730

[6] Zhang Y, Wu S, Liu W, Hu Z. Current status and future direction of duck hepatitis A virus vaccines. Avian Pathology. 2022. DOI: https://doi.org/10.1080/03079457.2022.2162367

[7] El-Sayed HS, Saad A, Tawfik WA, Adel A, Abdelmagid M, Momenah M, et al.. The role of turmeric and black pepper oil nanoemulsion in attenuating cytokine storm triggered by duck hepatitis A virus type I (DHAV-I)-induced infection in ducklings. Poultry Science. 2023. DOI: https://doi.org/10.1016/j.psj.2023.103404

[8] An H, Liu Y, Fang L, Shu M, Zhai Q, Chen J. Placenta-specific 8 facilitates the infection of duck hepatitis A virus type 1 by inhibiting the TLR7 MyD88-dependent signaling pathway. Poultry Science. 2023. DOI: https://doi.org/10.1016/j.psj.2023.102724

[9] Yang C, Shah PT, Bahoussi AN, Wu C, Wang L, Xing L. Duck hepatitis a virus: Full-length genome-based phylogenetic and phylogeographic view during 1986–2020. Virus Research. 2023. DOI: https://doi.org/10.1016/j.virusres.2023.199216

[10] Xu G, Yan H, Zhu Y, Xie Z, Zhang R, Jiang S. Duck hepatitis A virus type 1 transmission by exosomes establishes a productive infection in vivo and in vitro.. Veterinary Microbiology. 2022. DOI: https://doi.org/10.1016/j.vetmic.2022.109621

[11] Fehér E, Jakab S, Bali K, Kaszab E, Nagy B, Ihász K, et al.. Genomic Epidemiology and Evolution of Duck Hepatitis A Virus. Viruses. 2021. DOI: https://doi.org/10.3390/v13081592

[12] Liu Z, Ye Q, Cheng A, Ou X, Mao S, Sun D, et al.. A viroporin-like 2B protein of duck hepatitis A virus 1 that induces incomplete autophagy in DEF cells. Poultry Science. 2021. DOI: https://doi.org/10.1016/j.psj.2021.101331

[13] Rohaim M, Naggar RF, Abdelsabour MA, Ahmed BA, Hamoud MM, Ahmed KA, et al.. Insights into the Genetic Evolution of Duck Hepatitis A Virus in Egypt. Animals. 2021. DOI: https://doi.org/10.3390/ani11092741

[14] Wen X, Zhu D, Cheng A, Wang M, Chen S, Jia R, et al.. Molecular epidemiology of duck hepatitis a virus types 1 and 3 in China, 2010–2015. Transboundary and Emerging Diseases. 2018. DOI: https://doi.org/10.1111/tbed.12741

[15] Yehia N, Erfan A, Omar SE, Soliman M. Dual Circulation of Duck Hepatitis A Virus Genotypes 1 and 3 in Egypt. Avian diseases. 2020. DOI: https://doi.org/10.1637/aviandiseases-D-20-00075

[16] Zhang R, Yang Y, Lan J, Xie Z, Zhang X, Jiang S. Evidence of possible vertical transmission of duck hepatitis A virus type 1 in ducks.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13708

[17] Hassan T, Eid A, Ghanem I, Shahin A, Adael SAA, Mohamed FF. First Report of Duck Hepatitis A Virus 3 from Duckling Flocks of Egypt. Avian diseases. 2020. DOI: https://doi.org/10.1637/aviandiseases-D-19-00158

[18] Hisham I, Ellakany H, Selim A, Abdalla M, El-Abideen MAZ, Kilany WH, et al.. Comparative Pathogenicity of Duck Hepatitis A Virus-1 Isolates in Experimentally Infected Pekin and Muscovy Ducklings. Frontiers in Veterinary Science. 2020. DOI: https://doi.org/10.3389/fvets.2020.00234

[19] Xie J, Wang M, Cheng A, Zhao X, Liu M, Zhu D, et al.. Cytokine storms are primarily responsible for the rapid death of ducklings infected with duck hepatitis A virus type 1. Scientific Reports. 2018. DOI: https://doi.org/10.1038/s41598-018-24729-w

[20] Liu R, Shi S, Huang Y, Chen Z, Chen C, Cheng L, et al.. Comparative pathogenicity of different subtypes of duck hepatitis A virus in Pekin ducklings.. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2018.11.030

[21] Sun D, Wang M, Wen X, Cheng A, Jia R, Sun K, et al.. Cleavage of poly(A)-binding protein by duck hepatitis A virus 3C protease. Scientific Reports. 2017. DOI: https://doi.org/10.1038/s41598-017-16484-1

[22] Chen J, Zhang R, Lin S, Li P, Lan J, Song S, et al.. The Functional Role of the 3′ Untranslated Region and Poly(A) Tail of Duck Hepatitis A Virus Type 1 in Viral Replication and Regulation of IRES-Mediated Translation. Frontiers in Microbiology. 2018. DOI: https://doi.org/10.3389/fmicb.2018.02250

[23] Mansour S, Mohamed FF, ElBakrey RM, Eid A, Mor S, Goyal S. Outbreaks of Duck Hepatitis A Virus in Egyptian Duckling Flocks. Avian diseases. 2018. DOI: https://doi.org/10.1637/11975-092118-Reg.1

[24] Wang X, Zhang J, Meng R, Jiang Y, Liang S, Zhang Y, et al.. Host Differences Affecting Resistance and Susceptibility of the Second Generation of a Pekin Duck Flock to Duck Hepatitis A Virus Genotype 3. Frontiers in Microbiology. 2017. DOI: https://doi.org/10.3389/fmicb.2017.01128

[25] Zhang X, Cao C, Liu Y, Qi H, Zhang W, Hao C, et al.. Comparative liver transcriptome analysis in ducklings infected with duck hepatitis A virus 3 (DHAV-3) at 12 and 48 hours post-infection through RNA-seq. Veterinary Research. 2018. DOI: https://doi.org/10.1186/s13567-018-0545-7

[26] Kamomae M, Kameyama M, Ishii J, Nabe M, Ogura Y, Iseki H, et al.. An outbreak of duck hepatitis A virus type 1 infection in Japan. Journal of Veterinary Medical Science. 2017. DOI: https://doi.org/10.1292/jvms.16-0646

[27] Chen J, Zhang R, Lan J, Lin S, Li P, Gao J, et al.. IGF2BP1 Significantly Enhances Translation Efficiency of Duck Hepatitis A Virus Type 1 without Affecting Viral Replication. Biomolecules. 2019. DOI: https://doi.org/10.3390/biom9100594

[28] Zhu T, Qi B, Liu R, Jiang X, Lu R, Xiao L, et al.. Comparative pathogenicity of two subtypes (hepatitis-type and pancreatitis-type) of duck hepatitis A virus type 1 in experimentally infected Muscovy ducklings. Avian Pathology. 2019. DOI: https://doi.org/10.1080/03079457.2019.1605146

[29] Chen J, Zhang R, Lin S, Li P, Lan J, Gao J, et al.. Identification of a functional nuclear localization signal in 3Dpol/3CD of duck hepatitis A virus 1.. Virus Research. 2019. DOI: https://doi.org/10.1016/j.virusres.2019.197670

[30] Zou Z, Ma J, Huang K, Chen H, Liu Z, Jin M. Live Attenuated Vaccine Based on Duck Enteritis Virus against Duck Hepatitis A Virus Types 1 and 3. Frontiers in Microbiology. 2016. DOI: https://doi.org/10.3389/fmicb.2016.01613

[31] Chen J, Zhang R, Lin S, Li P, Lan J, Xie Z, et al.. Construction and characterization of an improved DNA-launched infectious clone of duck hepatitis a virus type 1. Virology Journal. 2017. DOI: https://doi.org/10.1186/s12985-017-0883-5

[32] Fu Q, Han X, Zhu C, Jiao W, Liu R, Feng Z, et al.. Development of the first officially licensed live attenuated duck hepatitis A virus type 3 vaccine strain HB80 in China and its protective efficacy against DHAV-3 infection in ducks. Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.104087

[33] Shawki MM, Abido OY, Saif MA, Sobh MS, Gado A, Elnaggar A, et al.. Comparative pathogenicity of duck hepatitis A virus genotype 3 in different duck breeds: Implications of the diagnosis and prevention of duck viral hepatitis.. Comparative Immunology, Microbiology & Infectious Diseases. 2024. DOI: https://doi.org/10.1016/j.cimid.2024.102256

[34] Liang S, Zhang J, Wang X, Xing G, Guo Z, Zhang Q, et al.. Selective analysis of resistance and susceptibility to duck hepatitis A virus genotype 3 in Pekin duck. Animal Research and One Health. 2023. DOI: https://doi.org/10.1002/aro2.36

[35] Wu L, Quan W, Zhang Y, Wang M, Ou X, Mao S, et al.. Attenuated Duck Hepatitis A Virus Infection Is Associated With High mRNA Maintenance in Duckling Liver via m6A Modification. Frontiers in Immunology. 2022. DOI: https://doi.org/10.3389/fimmu.2022.839677

[36] Liang S, Hu X, Guo Z, Luo D, Tang J, Ji Z, et al.. Comparative transcriptome reveals the effect of IFITM1 on differential resistance to duck hepatitis A virus genotype 3 in Pekin ducks.. Virus Research. 2022. DOI: https://doi.org/10.1016/j.virusres.2022.198930

[37] Liang S, Wang M, Zhang B, Feng Y, Tang J, Xie M, et al.. NOD1 Is Associated With the Susceptibility of Pekin Duck Flock to Duck Hepatitis A Virus Genotype 3. Frontiers in Immunology. 2021. DOI: https://doi.org/10.3389/fimmu.2021.766740

[38] Ming K, He M, Su L, Du H, Wang D, Wu Y, et al.. The inhibitory effect of phosphorylated Codonopsis pilosula polysaccharide on autophagosomes formation contributes to the inhibition of duck hepatitis A virus replication. Poultry Science. 2020. DOI: https://doi.org/10.1016/j.psj.2019.11.060

[39] Liu Y, Cheng A, Wang M, Mao S, Ou X, Yang Q, et al.. Duck Hepatitis A Virus Type 1 Induces eIF2α Phosphorylation-Dependent Cellular Translation Shutoff via PERK/GCN2. Frontiers in Microbiology. 2021. DOI: https://doi.org/10.3389/fmicb.2021.624540

[40] Liu Y, Li Y, Wang M, Cheng A, Ou X, Mao S, et al.. Duck hepatitis A virus type 1 mediates cell cycle arrest in the S phase. Virology Journal. 2021. DOI: https://doi.org/10.1186/s12985-022-01839-6

[41] Wu F, Lu F, Fan X, Pan Q, Zhao S, Sun H, et al.. Development of a live attenuated duck hepatitis a virus type 3 vaccine (strain SD70).. Vaccine. 2020. DOI: https://doi.org/10.1016/j.vaccine.2020.05.030

[42] Liang S, Xie M, Tang J, Wang M, Zhang D, Hou S. Proteomics reveals the effect of type I interferon on the pathogenicity of duck hepatitis A virus genotype 3 in Pekin ducks.. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2020.108813

[43] Liang S, Tang J, Wang X, Wen Z, Xie M, Wu Y, et al.. Effect of duck hepatitis A virus genotype 3 infection on glucose metabolism of Pekin ducklings and underlying mechanism.. Gene. 2020. DOI: https://doi.org/10.1016/j.gene.2020.144710

[44] Lai Y, Zeng N, Wang M, Cheng A, Yang Q, Wu Y, et al.. The VP3 protein of duck hepatitis A virus mediates host cell adsorption and apoptosis. Scientific Reports. 2019. DOI: https://doi.org/10.1038/s41598-019-53285-0

[45] Xue W, Zhao Q, Li P, Zhang R, Lan J, Wang J, et al.. Identification and characterization of a novel nanobody against duck hepatitis A virus type 1.. Virology. 2019. DOI: https://doi.org/10.1016/j.virol.2018.12.013

[46] Wen X, Guo J, Sun D, Wang M, Cao D, Cheng A, et al.. Mutations in VP0 and 2C Proteins of Duck Hepatitis A Virus Type 3 Attenuate Viral Infection and Virulence. Vaccines. 2019. DOI: https://doi.org/10.3390/vaccines7030111

[47] Wang M, Chai L, Liang S, Lv J, Yang L, Qu S, et al.. Fetal Calf Serum Exerts an Inhibitory Effect on Replication of Duck Hepatitis A Virus Genotype 1 in Duck Embryo Fibroblast Cells. Viruses. 2020. DOI: https://doi.org/10.3390/v12010080

[48] Mao S, Ou X, Wang M, Di S, Yang Q, Wu Y, et al.. Duck hepatitis A virus 1 has lymphoid tissue tropism altering the organic immune responses of mature ducks.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13966

[49] Ou X, Mao S, Cao J, Cheng A, Wang M, Zhu D, et al.. Comparative analysis of virus-host interactions caused by a virulent and an attenuated duck hepatitis A virus genotype 1. PLoS ONE. 2017. DOI: https://doi.org/10.1371/journal.pone.0178993

[50] Wang M, Li Z, Liu H, Wang X, Zhang D. Effect of fetal calf serum on propagation of duck hepatitis A virus genotype 3 in duck embryo fibroblast cells. BMC Veterinary Research. 2019. DOI: https://doi.org/10.1186/s12917-019-1904-y

[51] Zhang Q, Yu G, Ding X, Zhang K, Sun W, Li Q, et al.. A rapid simultaneous detection of duck hepatitis A virus 3 and novel duck reovirus based on RPA CRISPR Cas12a/Cas13a.. International Journal of Biological Macromolecules. 2024. DOI: https://doi.org/10.1016/j.ijbiomac.2024.133246

[52] Qiu Q, Hu R, Liu Z, Yan L, Dai X, Xing C, et al.. Taqman-probe-based multiplex real-time RT-QPCR for simultaneous detection of duck tembusu virus, novel duck reovirus, duck hepatitis a type 1 virus and duck hepatitis a type 3 virus. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.105508

[53] Li Y, Cui Y, Liu H, Wang J, Li Y, Wang Y. Establishment of Duplex SYBR Green I-based Real-time PCR Assay for Simultaneous Detection of Duck Hepatitis A Virus-1 and Duck Astrovirus-3. Avian diseases. 2021. DOI: https://doi.org/10.1637/aviandiseases-D-20-00115

[54] Zhang R, Chen J, Zhang J, Yang Y, Li P, Lan J, et al.. Novel duck hepatitis A virus type 1 isolates from adult ducks showing egg drop syndrome.. Veterinary Microbiology. 2018. DOI: https://doi.org/10.1016/j.vetmic.2018.05.023

[55] Mao S, Wang M, Ou X, Sun D, Cheng A, Zhu D, et al.. Virologic and Immunologic Characteristics in Mature Ducks with Acute Duck Hepatitis A Virus 1 Infection. Frontiers in Immunology. 2017. DOI: https://doi.org/10.3389/fimmu.2017.01574

[56] Chen X, Chen Y, Liu C, Li X, Liu H, Yin X, et al.. Improved one-tube RT-PCR method for simultaneous detection and genotyping of duck hepatitis A virus subtypes 1 and 3. PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0219750

[57] Truong T, Cheng L. Development of a Subunit Vaccine against Duck Hepatitis A Virus Serotype 3. Vaccines. 2022. DOI: https://doi.org/10.3390/vaccines10040523

[58] . duck hepatitis A virus. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.84185

[59] Zhang X, Zhang R, Wang J, Sui N, Xu G, Yan H, et al.. Construction of Recombinant Lactococcus lactis Strain Expressing VP1 Fusion Protein of Duck Hepatitis A Virus Type 1 and Evaluation of Its Immune Effect. Vaccines. 2021. DOI: https://doi.org/10.3390/vaccines9121479

[60] Song S, Li P, Zhang R, Chen J, Lan J, Lin S, et al.. Oral vaccine of recombinant Lactococcus lactis expressing the VP1 protein of duck hepatitis A virus type 3 induces mucosal and systemic immune responses.. Vaccine. 2019. DOI: https://doi.org/10.1016/j.vaccine.2019.06.026

[61] Ye L, Zhou S, Zhang H, Zhang T, Yang D, Hong X. A meta-analysis for vaccine protection rate of duck hepatitis a virus in mainland China in 2009–2021. BMC Veterinary Research. 2023. DOI: https://doi.org/10.1186/s12917-023-03744-8

[62] Wang A, Liu L, Gu L, Guo C, Wu S, Feng Q, et al.. Protection against duck hepatitis a virus type 1 conferred by a recombinant avian adeno‐associated virus. Poultry Science. 2019. DOI: https://doi.org/10.3382/ps/pey325

[63] Zhou S, Zhang S, Wang M, Cheng A, Zhu D, Chen S, et al.. Development and evaluation of an indirect ELISA based on recombinant nonstructural protein 3A to detect antibodies to duck hepatitis A virus type 1.. Journal of Virological Methods. 2019. DOI: https://doi.org/10.1016/j.jviromet.2019.03.012

[64] Ren Y, Yue H, Zhu L, Kan R, Tang C, Zhang B. A reverse transcription-insulated isothermal PCR assay for the detection of duck hepatitis A virus type 3 based on the POCKIT™ system.. Journal of Virological Methods. 2019. DOI: https://doi.org/10.1016/j.jviromet.2019.05.006

[65] Wen X, Cheng A, Wang M, Jia R, Zhu D, Chen S, et al.. Detection, differentiation, and VP1 sequencing of duck hepatitis A virus type 1 and type 3 by a 1-step duplex reverse-transcription PCR assay.. Poultry Science. 2014. DOI: https://doi.org/10.3382/ps.2014-04024

[66] Yang F, Liu P, Li X, Liu R, Gao L, Cui H, et al.. Recombinant Duck Enteritis Virus-Vectored Bivalent Vaccine Effectively Protects Against Duck Hepatitis A Virus Infection in Ducks. Frontiers in Microbiology. 2021. DOI: https://doi.org/10.3389/fmicb.2021.813010

[67] Wang A, Liu L, Gu L, Wu S, Guo C, Feng Q, et al.. Expression of duck hepatitis A virus type 1 VP3 protein mediated by avian adeno-associated virus and its immunogenicity in ducklings.. Acta virologica. 2019. DOI: https://doi.org/10.4149/av_2019_104

[68] Zhang X, Zhang W, Liu Y, Qi H, Hao C, Zhang W, et al.. Molecular cloning and mRNA expression of IFIT5 in tissues of ducklings infected with virulent duck hepatitis A virus type 3.. Research in Veterinary Science. 2019. DOI: https://doi.org/10.1016/j.rvsc.2019.04.003

[69] Su L, Wang R, Qiu T, Wang J, Meng J, Zhu J, et al.. The protective effect of baicalin on duck hepatitis A virus type 1-induced duck hepatic mitochondria dysfunction by activating nuclear erythroid 2-related factor 2/antioxidant responsive element signaling pathway. Poultry Science. 2021. DOI: https://doi.org/10.1016/j.psj.2021.101032

[70] Chen Y, Yang Y, Wang F, Yang X, Yao F, Ming K, et al.. Antiviral effect of baicalin phospholipid complex against duck hepatitis A virus type 1. Poultry Science. 2018. DOI: https://doi.org/10.3382/ps/pey155